サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1797334

注入薬の世界市場

Infused Drugs

出版日
ページ情報
英文 285 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.92円
注入薬の世界市場
出版日: 2025年08月25日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 285 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

注入薬の世界市場は2030年までに118億米ドルに達する見込み

2024年に82億米ドルと推定される注入薬の世界市場は、分析期間2024-2030年にCAGR 6.2%で成長し、2030年には118億米ドルに達すると予測されます。本レポートで分析したセグメントの一つである低分子医薬品は、CAGR7.5%を記録し、分析期間終了時には76億米ドルに達すると予想されます。生物製剤セグメントの成長率は、分析期間中CAGR 4.1%と推定されます。

米国市場は22億米ドルと推定、中国はCAGR 10.0％で成長予測

米国の注入薬市場は2024年に22億米ドルと推定されます。世界第2位の経済大国である中国は、2024年から2030年の分析期間においてCAGR 10.0%で推移し、2030年には25億米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.9%と6.1%と予測されています。欧州では、ドイツがCAGR 4.1%で成長すると予測されています。

世界の注入薬市場- 主要動向と促進要因のまとめ

注入薬が各治療分野で支持を集める理由とは？

注入薬は、静脈内または皮下ルートで血流または組織に直接投与され、迅速、正確、または長時間の投与が必要な病態の管理に不可欠です。これらの薬剤は、経口または局所治療が不十分な腫瘍学、自己免疫疾患、希少疾患、慢性感染症などで広く使用されています。輸液はバイオアベイラビリティをコントロールすることができ、消化管吸収不良や患者のコンプライアンス違反に関する問題を回避することができます。

生物学的製剤や標的治療薬の進歩により、関節リウマチ、多発性硬化症、がんなどの治療における注入薬の役割は拡大しています。注入モノクローナル抗体、免疫療法、酵素補充療法は、非常に特異的で疾患修飾的な治療選択肢を提供しています。個別化医療が普及するにつれ、注入薬は遺伝子やバイオマーカーのプロファイルに基づいて調整され、複雑な疾患領域における治療精度と転帰を向上させています。

デリバリーシステムとケア環境はどのように進化しているのか？

注入薬の投与は、病院だけでなく、外来診療所、在宅医療、専門輸液センターへとシフトしています。ポータブル輸液ポンプや簡易輸液キットは、長期治療を必要とする患者にとって、より柔軟で快適な治療を可能にしています。在宅輸液サービスは、遠隔監視と看護師による投与支援によって、特に反復投与が必要な慢性疾患向けに拡大しています。

ドラッグデリバリーシステムも、スマートポンプ、クローズドシステムトランスファーデバイス、輸液間隔の延長を可能にする製剤などで進歩しています。これらの技術革新は感染リスクを低減し、患者の安全性を高め、アドヒアランスを向上させます。高所得市場と新興市場の両方において、治療費を削減し、アクセスを改善するために、生物製剤のバイオシミラー輸液が導入されています。また、輸液時間を短縮し、輸液関連反応を減らすために、製剤技術の最適化も進んでいます。

市場の需要が増加している分野と主なエンドユーザーは？

がん領域は依然として注入薬の最大セグメントであり、がん罹患率の上昇と標的治療薬の使用拡大により、世界需要のかなりの割合を占めています。クローン病、乾癬、全身性狼瘡などの自己免疫疾患も輸液薬使用の主な要因です。病院薬局、外来輸液クリニック、専門医療センターが主な投与場所です。

需要は先進国でも新興諸国でも増加しています。北米は、専門治療施設の存在と償還の枠組みにより、利用率でリードしています。欧州はバイオシミラーと在宅輸液モデルの強力な導入でこれに続きます。アジア太平洋は、ヘルスケアへのアクセス向上、がん検診プログラム、政府による慢性期医療への取り組みにより成長を遂げています。輸液製剤の需要は、移植医療、感染症管理、希少代謝疾患によっても支えられています。

注入薬市場の成長の原動力は？

注入薬市場の成長は、慢性疾患や希少疾患の罹患率の増加、生物学的療法の進歩、外来および在宅輸液サービスの採用増加など、いくつかの要因によってもたらされます。携帯型輸液デバイスやプログラム可能な輸液デバイスを含む送達システムの技術的改良は、より安全で便利な治療環境を支えています。また、自己免疫疾患やがん領域における輸液免疫療法や長時間作用型生物学的製剤の適応拡大も需要を支えています。

外来治療、専門クリニック、在宅輸液プログラムにおけるエンドユースの拡大は、入院投与によるコスト負担を軽減する一方で、治療へのアクセシビリティを高めています。バイオシミラーの開発と在宅輸注を支援する支払側の取り組みにより、費用対効果の高い治療経路が構築されつつあります。プレシジョンメディシンとコンパニオンダイアグノスティックスの役割の高まりは、標的作用機序を有する高有効性の注入薬に対する需要を強めています。このような動向は、複数の疾患領域やケアモデルにまたがる輸液療法の世界市場を総体的に強化しています。

セグメント

薬剤タイプ（低分子、生物）、治療領域（がん、消化器疾患、関節リウマチ、免疫不全、循環器疾患、神経疾患、糖尿病、その他治療領域）

調査対象企業の例

  • AbbVie Inc.
  • Amgen Inc.
  • Amneal Pharmaceuticals Inc.
  • Apotex Inc.
  • AstraZeneca plc
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Endo International plc
  • Hikma Pharmaceuticals plc
  • Parenteral Drugs（India）Ltd.
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi S.A.
  • Stada Arzneimittel AG
  • Teva Pharmaceutical Industries Ltd.
  • Weefsel Pharma（Weefsel Biopharma）
  • Wockhardt Ltd.
  • Zydus Cadila

AIインテグレーション

当社は、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP38949

Global Infused Drugs Market to Reach US$11.8 Billion by 2030

The global market for Infused Drugs estimated at US$8.2 Billion in the year 2024, is expected to reach US$11.8 Billion by 2030, growing at a CAGR of 6.2% over the analysis period 2024-2030. Small Molecules Drug, one of the segments analyzed in the report, is expected to record a 7.5% CAGR and reach US$7.6 Billion by the end of the analysis period. Growth in the Biologics Drug segment is estimated at 4.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.2 Billion While China is Forecast to Grow at 10.0% CAGR

The Infused Drugs market in the U.S. is estimated at US$2.2 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.5 Billion by the year 2030 trailing a CAGR of 10.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.9% and 6.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.1% CAGR.

Global Infused Drugs Market - Key Trends & Drivers Summarized

Why Are Infused Drugs Gaining Preference Across Therapeutic Areas?

Infused drugs, administered directly into the bloodstream or tissue via intravenous or subcutaneous routes, are essential in managing conditions that require rapid, precise, or long-duration dosing. These drugs are widely used in oncology, autoimmune diseases, rare disorders, and chronic infections where oral or topical treatments are inadequate. Infusion allows for controlled bioavailability and bypasses issues related to poor gastrointestinal absorption or patient non-compliance.

Advances in biologics and targeted therapies have expanded the role of infused drugs in treating conditions such as rheumatoid arthritis, multiple sclerosis, and cancer. Infused monoclonal antibodies, immunotherapies, and enzyme replacement therapies are providing highly specific, disease-modifying treatment options. As personalized medicine becomes more prevalent, infused drugs are being tailored based on genetic and biomarker profiles, improving therapeutic precision and outcomes in complex disease areas.

How Are Delivery Systems and Care Settings Evolving?

The administration of infused drugs is shifting beyond hospitals to outpatient clinics, home care, and specialized infusion centers. Portable infusion pumps and simplified infusion kits are enabling greater flexibility and comfort for patients requiring long-term treatment. Home infusion services are expanding, particularly for chronic conditions that need recurrent dosing, supported by remote monitoring and nurse-assisted administration.

Drug delivery systems are also advancing with smart pumps, closed-system transfer devices, and formulations that allow extended infusion intervals. These innovations reduce infection risks, increase patient safety, and improve adherence. Biosimilar versions of infused biologics are being introduced to reduce treatment costs and improve access in both high-income and emerging markets. Formulation technologies are also being optimized to shorten infusion times and reduce infusion-related reactions.

Where Is Market Demand Increasing, and Who Are the Main End-Users?

Oncology remains the largest segment for infused drugs, accounting for a substantial share of global demand due to the rise in cancer incidence and expanded use of targeted therapies. Autoimmune diseases such as Crohn’s disease, psoriasis, and systemic lupus are also major contributors to infusion drug usage. Hospital pharmacies, outpatient infusion clinics, and specialty care centers are the primary settings for administration.

Demand is increasing in both developed and developing countries. North America leads in utilization due to the presence of specialized treatment facilities and reimbursement frameworks. Europe follows with strong adoption of biosimilars and home-based infusion models. Asia Pacific is experiencing growth due to rising healthcare access, cancer screening programs, and government-backed chronic care initiatives. Infusion drug demand is also supported by transplant care, infectious disease management, and rare metabolic disorders.

What Is Driving Growth in the Infused Drugs Market?

Growth in the infused drugs market is driven by several factors including increasing incidence of chronic and rare diseases, advances in biologic therapies, and rising adoption of outpatient and home-based infusion services. Technological improvements in delivery systems, including portable and programmable infusion devices, are supporting safer and more convenient treatment settings. Demand is also supported by expanding indications for infused immunotherapies and long-acting biologics across autoimmune and oncology domains.

End-use expansion in ambulatory care, specialty clinics, and home infusion programs is increasing treatment accessibility while reducing the cost burden of inpatient administration. Development of biosimilars and payer initiatives to support home infusions are creating cost-effective treatment pathways. The growing role of precision medicine and companion diagnostics is strengthening demand for high-efficacy infused drugs with targeted mechanisms of action. These trends are collectively reinforcing the global market for infused therapies across multiple disease areas and care models.

SCOPE OF STUDY:

The report analyzes the Infused Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Type (Small Molecules Drug, Biologics Drug); Therapeutic Area (Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area, Diabetes Therapeutic Area, Other Therapeutic Areas)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

  • AbbVie Inc.
  • Amgen Inc.
  • Amneal Pharmaceuticals Inc.
  • Apotex Inc.
  • AstraZeneca plc
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Endo International plc
  • Hikma Pharmaceuticals plc
  • Parenteral Drugs (India) Ltd.
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi S.A.
  • Stada Arzneimittel AG
  • Teva Pharmaceutical Industries Ltd.
  • Weefsel Pharma (Weefsel Biopharma)
  • Wockhardt Ltd.
  • Zydus Cadila

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Infused Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Chronic and Autoimmune Diseases Drives Demand for Long-Term Administration of Infused Therapies
    • Expansion of Biologic Drug Development Pipelines Strengthens Growth in IV-Delivered Monoclonal Antibodies and Targeted Treatments
    • OEM Innovation in Formulation Stability and Infusion Device Compatibility Enhances Safety and Efficacy of Infused Medications
    • Growing Shift Toward Outpatient and Home Infusion Models Throws Spotlight on Portable and Self-Administered Infusion Systems
    • Surge in Cancer Treatment Protocols Involving Chemotherapy and Immunotherapy Supports Use of Infused Drug Regimens
    • OEM Focus on Closed-System Drug Transfer Devices and Catheter Safety Enhances Risk Management During Infusion Procedures
    • Increasing Role of Specialty Pharmacies and Infusion Clinics Promotes Access to High-Cost Infused Therapies
    • Expansion of Value-Based Care Models Drives Emphasis on Cost-Effectiveness and Outcome Monitoring for Infused Drugs
    • OEM Integration of Infusion Monitoring Software With EHR Systems Improves Documentation and Clinical Oversight
    • Rising Demand for Personalized Dosing and Weight-Based Infusion Protocols Supports Precision Medicine Approaches
    • Growth in Pediatric and Rare Disease Therapies Fuels Innovation in Low-Volume, High-Potency Infused Drug Formats
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Infused Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Infused Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Infused Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Infused Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Small Molecules Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Small Molecules Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Small Molecules Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Biologics Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Biologics Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Biologics Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Other Therapeutic Areas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Oncology Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Oncology Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Oncology Therapeutic Area by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Gastrointestinal Diseases Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Gastrointestinal Diseases Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Gastrointestinal Diseases Therapeutic Area by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Rheumatoid Arthritis Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Rheumatoid Arthritis Therapeutic Area by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Immune Deficiencies Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Immune Deficiencies Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Immune Deficiencies Therapeutic Area by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Cardiology Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Cardiology Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Cardiology Therapeutic Area by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Neurology Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Neurology Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Neurology Therapeutic Area by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Diabetes Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Diabetes Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: World 16-Year Perspective for Diabetes Therapeutic Area by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Infused Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 35: USA Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • JAPAN
    • Infused Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: Japan 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Japan 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • CHINA
    • Infused Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 53: China Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: China 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 56: China Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: China 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • EUROPE
    • Infused Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Infused Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Infused Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Infused Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: Europe 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Europe 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • FRANCE
    • Infused Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 68: France Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: France Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: France 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 71: France Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: France Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: France 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • GERMANY
    • Infused Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 74: Germany Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Germany Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Germany 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 77: Germany Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Germany Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Germany 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 80: Italy Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Italy Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Italy 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 83: Italy Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Italy Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Italy 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Infused Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 86: UK Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: UK Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: UK 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 89: UK Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: UK Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: UK 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 92: Spain Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Spain Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Spain 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 95: Spain Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Spain Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Spain 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 98: Russia Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Russia Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Russia 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 101: Russia Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Russia Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Russia 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of Europe Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Rest of Europe 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 107: Rest of Europe Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Rest of Europe Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Rest of Europe 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Infused Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Infused Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Infused Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 16-Year Perspective for Infused Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Asia-Pacific Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: Asia-Pacific 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 116: Asia-Pacific Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Asia-Pacific Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: Asia-Pacific 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Infused Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 119: Australia Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Australia Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: Australia 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 122: Australia Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Australia Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: Australia 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • INDIA
    • Infused Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 125: India Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: India Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: India 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 128: India Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: India Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: India 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 131: South Korea Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: South Korea Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: South Korea 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 134: South Korea Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: South Korea Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: South Korea 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 137: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Asia-Pacific Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Rest of Asia-Pacific 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 140: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Asia-Pacific Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Rest of Asia-Pacific 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Infused Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Infused Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Infused Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Latin America 16-Year Perspective for Infused Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 146: Latin America Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Latin America Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Latin America 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 149: Latin America Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Latin America Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Latin America 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 152: Argentina Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Argentina Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Argentina 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 155: Argentina Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Argentina Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Argentina 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 158: Brazil Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Brazil Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Brazil 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 161: Brazil Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Brazil Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Brazil 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 164: Mexico Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Mexico Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Mexico 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 167: Mexico Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Mexico Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Mexico 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 170: Rest of Latin America Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Rest of Latin America Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Rest of Latin America 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 173: Rest of Latin America Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Rest of Latin America Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Rest of Latin America 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Infused Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Infused Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Infused Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Middle East 16-Year Perspective for Infused Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 179: Middle East Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Middle East Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Middle East 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 182: Middle East Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Middle East Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Middle East 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 185: Iran Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Iran Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Iran 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 188: Iran Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Iran Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: Iran 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 191: Israel Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Israel Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Israel 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 194: Israel Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Israel Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: Israel 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 197: Saudi Arabia Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Saudi Arabia Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: Saudi Arabia 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 200: Saudi Arabia Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Saudi Arabia Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Saudi Arabia 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 203: UAE Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: UAE Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: UAE 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 206: UAE Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: UAE Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: UAE 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 209: Rest of Middle East Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Rest of Middle East Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Rest of Middle East 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 212: Rest of Middle East Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Rest of Middle East Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 214: Rest of Middle East 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030
  • AFRICA
    • Infused Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 215: Africa Recent Past, Current & Future Analysis for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Africa Historic Review for Infused Drugs by Drug Type - Small Molecules Drug and Biologics Drug Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 217: Africa 16-Year Perspective for Infused Drugs by Drug Type - Percentage Breakdown of Value Sales for Small Molecules Drug and Biologics Drug for the Years 2014, 2025 & 2030
    • TABLE 218: Africa Recent Past, Current & Future Analysis for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Africa Historic Review for Infused Drugs by Therapeutic Area - Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 220: Africa 16-Year Perspective for Infused Drugs by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Oncology Therapeutic Area, Gastrointestinal Diseases Therapeutic Area, Rheumatoid Arthritis Therapeutic Area, Immune Deficiencies Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area and Diabetes Therapeutic Area for the Years 2014, 2025 & 2030

IV. COMPETITION